Opinion

Video

Value-Based Care Models Optimizing Ph+ ALL Patient Care

Vivian Tambe Ebot-Tar, PharmD, MBA, leads a discussion on value-based care models based on real-world evidence for the treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA; Jonathan Abbas, MD; Elias Jabbour, MD; James K. McCloskey, MD; Vivian Tambe Ebot-Tar, PharmD, MBA.

The discussants examined the role of value-based care models in optimizing management of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). Dr Ebot-Tar discussed how such agreements can facilitate access to innovative therapies while aligning costs to outcomes. She shared an example of analyzing real-world chimeric antigen receptor T-cell therapy episode costs and durability to identify opportunities to potentially improve value. Ongoing engagement between payers and research centers provides insights to inform coverage decisions for emerging therapies with still-evolving data. Dr Haumschild concurred that direct provider input helps plans design appropriate medical policies for specialized conditions like Ph+ ALL.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.

Related Videos
A panel of 4 experts on PDTs
A panel of 4 experts on PDTs
A panel of 5 experts on Alzheimer disease
A panel of 5 experts on Alzheimer disease
Video 2 - "SunRISe-1: Examining Combination Therapy for HR NMIBC"
Video 1 - "Comparing Long-Term Efficacy of Bladder-Preserving Therapies for NMIBC "
Ravin Ratan, MD, MEd, MD Anderson
Dr Migvis Monduy
Paul Frohna, MD, PhD, PharmD.
Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Center.
Related Content
CH LogoCenter for Biosimilars Logo